The company found themselves facing competitive tenders for the first time in this disease space - t...
Read moreAn affordable and sustainable market access landscape is key to ensure patient access to life-saving...
Read moreThe study looks at the direct, indirect and mortality-related costs of 24 rare diseases across five ...
Read moreAccording to updated guidelines published by NICE, patients newly diagnosed with glaucoma and ocular...
Read moreThis study investigates costs of gene/acute therapies versus chronic treatments for rare diseases, o...
Read moreFollowing a series of FOI requests to CCGs, MTG said a number of CCGs are currently restricting acce...
Read morePharmaceutical companies are able to charge significantly higher prices as these products are addres...
Read moreUpdates on the latest news on NICE's Value Based Assessment, as well as the approval of ultra-orphan...
Read more